Suppr超能文献

组织型纤溶酶原激活剂对猫急性心肌缺血的有益作用。

Beneficial effects of tissue-type plasminogen activator in acute myocardial ischemia in cats.

作者信息

Darius H, Yanagisawa A, Brezinski M E, Hock C E, Lefer A M

出版信息

J Am Coll Cardiol. 1986 Jul;8(1):125-31. doi: 10.1016/s0735-1097(86)80102-4.

Abstract

Tissue-type plasminogen activator is a new thrombolytic agent that dissolves intravascular thrombi in coronary and peripheral vessels with less pronounced systemic lysis than that produced by streptokinase. Plasminogen activator was shown to induce reperfusion, and to salvage ischemic myocardium, by lysing experimentally induced coronary artery thrombi. The effect of a melanoma cell-derived tissue-type plasminogen activator was studied in cat myocardium rendered ischemic by coronary artery ligation for 2 hours and reperfused for another 4 hours. Plasminogen activator was infused at a rate of 500 IU X kg-1 X min-1 for the first 30 minutes of reperfusion. The marked increase in plasma creatine kinase activity during reperfusion was significantly lower in plasminogen activator-treated cats at 4, 5 and 6 hours, with 7.7 +/- 1.5 X 10(-3) IU X mg protein-1 (n = 8) in the plasminogen activator group versus 17.8 +/- 3.5 X 10(-3) IU X mg protein-1 (n = 7) in the vehicle group at 6 hours (mean +/- SEM). The area at risk in the two ischemic groups was not different, being 14.6 +/- 1.5 and 16.6 +/- 1.4% of total left ventricular mass for the treated and untreated groups, respectively. However, the mass of necrotic tissue determined histochemically was significantly lower in the plasminogen activator-treated group, accounting for 29.5 +/- 3.9% of the area at risk compared with 46.8 +/- 4.2% of area at risk in cats receiving only the vehicle (p less than 0.02).(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

组织型纤溶酶原激活剂是一种新型溶栓剂,它能溶解冠状动脉和外周血管内的血栓,与链激酶相比,全身溶栓作用较弱。通过溶解实验诱导的冠状动脉血栓,纤溶酶原激活剂被证明可诱导再灌注并挽救缺血心肌。研究了黑色素瘤细胞衍生的组织型纤溶酶原激活剂对冠状动脉结扎2小时并再灌注4小时的猫心肌的作用。在再灌注的前30分钟,以500 IU·kg-1·min-1的速率输注纤溶酶原激活剂。再灌注期间血浆肌酸激酶活性的显著升高在纤溶酶原激活剂治疗的猫中,在4、5和6小时时显著降低,纤溶酶原激活剂组在6小时时为7.7±1.5×10(-3) IU·mg蛋白-1(n = 8),而载体组为17.8±3.5×10(-3) IU·mg蛋白-1(n = 7)(平均值±标准误)。两个缺血组的危险面积无差异,治疗组和未治疗组分别占左心室总质量的14.6±1.5%和16.6±1.4%。然而,组织化学测定的坏死组织质量在纤溶酶原激活剂治疗组中显著较低,占危险面积的29.5±3.9%,而仅接受载体的猫中为危险面积的46.8±4.2%(p<0.02)。(摘要截短于250字)

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验